ANRO vs. ESPR, AMRN, HRTX, ERAS, HROW, NKTX, NATR, ADCT, RANI, and MREO
Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Esperion Therapeutics (ESPR), Amarin (AMRN), Heron Therapeutics (HRTX), Erasca (ERAS), Harrow Health (HROW), Nkarta (NKTX), Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), Rani Therapeutics (RANI), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical preparations" industry.
Alto Neuroscience (NYSE:ANRO) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
Alto Neuroscience has higher earnings, but lower revenue than Esperion Therapeutics.
47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Esperion Therapeutics had 37 more articles in the media than Alto Neuroscience. MarketBeat recorded 38 mentions for Esperion Therapeutics and 1 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 1.73 beat Esperion Therapeutics' score of 0.19 indicating that Alto Neuroscience is being referred to more favorably in the media.
Alto Neuroscience currently has a consensus price target of $32.33, suggesting a potential upside of 139.68%. Esperion Therapeutics has a consensus price target of $9.33, suggesting a potential upside of 326.18%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Alto Neuroscience.
Alto Neuroscience has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -37.65%.
Esperion Therapeutics received 594 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 69.85% of users gave Esperion Therapeutics an outperform vote.
Summary
Alto Neuroscience beats Esperion Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Alto Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alto Neuroscience Competitors List
Related Companies and Tools
